Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Zohydro v. Massachusetts = Wyeth v. Levine? State Asserts Power To Seek Label Change

This article was originally published in The Pink Sheet Daily

Executive Summary

Arguing for its right to ban Zogenix Inc.’s opioid, Massachusetts contends that FDA clearance of a drug for marketing is a “gateway approval” that does not preempt states from imposing stricter requirements on a product.

You may also be interested in...

Zohydro Court Win: Deep Splash, But Few Ripples

Declaring that FDA product approval cannot be voided by Massachusetts, federal judge erases what could have been a strong challenge to agency authority; ruling is unlikely to change other state/federal dynamics, however.

Supreme Court’s Wyeth v. Levine Ruling Returns Industry To Status Quo On Pre-Emption

The court finds that FDA-approved labeling does not pre-empt individuals from bringing product liability suits under state law.

Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs

GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts